Loading...
•
Sep 30, 2022
GoodRx Q3 2022 Earnings Report
GoodRx's third quarter results exceeded expectations and addressed the grocer issue.
Key Takeaways
GoodRx's Q3 2022 earnings report revealed a total revenue of $187.3 million, surpassing previous guidance. Despite a net loss of $41.71 million, the company saw double-digit growth in subscription and pharma manufacturer solutions platforms. The company is prioritizing profitability and cash flow.
Total revenue reached $187.3 million, exceeding prior guidance.
Net loss amounted to $41.71 million, with a net loss margin of 22.3%.
Adjusted EBITDA stood at $52.0 million, resulting in an Adjusted EBITDA Margin of 27.8%, also exceeding expectations.
Net cash provided by operating activities was $33.7 million.
Revenue by Segment
Forward Guidance
For the fourth quarter, the company anticipates total revenue of approximately $175 million to $180 million and Adjusted EBITDA Margins in the low-to-mid-twenty-percent range.
Positive Outlook
- Focus on Adjusted EBITDA growth.
- Focus on margin improvement.
- Focus on cash conversion.
- Actions taken in relation to costs and expenses.
- Reprioritized spending across the business with the objective of greater efficiency.
Challenges Ahead
- Total Revenue ~$175-$180 million
- Year over year change ~(18%) - (16%)
- Includes a combined $45 million to $50 million estimated impact to prescription transactions revenue related to the previously disclosed grocer issue
- Includes continued consumer engagement efforts
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...